Apremilast in patients with moderate to severe psoriasis: Results of a phase 3, randomized, controlled trial (ESTEEM 2)

被引：0
|
作者：
Mrowietz, U. [1 ]
Paul, C. [2 ]
Gooderham, M. [3 ]
Cather, J. [4 ]
Poulin, Y. [5 ]
Girolomoni, G. [6 ]
Ferrandiz, C. [7 ]
Gottlieb, A. [8 ]
Hu, C. C. [9 ]
Day, R. [9 ]
Crowley, J. [10 ]
机构：
[1] Univ Hosp Schleswig Holstein, Kiel, Germany
[2] Toulouse Univ, Hop Larrey, Toulouse, France
[3] SKiN Ctr Dermatol, Peterborough, ON, Canada
[4] Modern Res Associates, Dallas, TX USA
[5] Ctr Rech Dermatol Quebec Metropolitain, Quebec City, PQ, Canada
[6] Univ Verona, I-37100 Verona, Italy
[7] Hosp Badalona Germans Trias & Pujol, Badalona, Spain
[8] Tufts Med Ctr, Boston, MA USA
[9] Celgene Corp, Warren, MI USA
[10] Bakersfield Dermatol, Bakersfield, CA USA
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2015年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
FV08/02
引用
收藏
页码：93 / 94
页数：2
相关论文
共 50 条
  • [21] Efalizumab for patients with moderate to severe plaque psoriasis - A randomized controlled trial
    Gordon, KB
    Papp, KA
    Hamilton, TK
    Walicke, PA
    Dummer, W
    Li, N
    Bresnahan, BW
    Menter, A
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (23): : 3073 - 3080
  • [22] Effect of apremilast on patient-reported outcomes in patients with moderate to severe plaque psoriasis in the ESTEEM 1 trial
    Armstrong, A. W.
    Griffiths, C.
    Tencer, T.
    Li, S.
    Zhang, F.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 67 - 67
  • [23] Two-year safety of apremilast in patients with moderate to severe plaque psoriasis: Results from ESTEEM 1
    Papp, K.
    Reich, K.
    Sobell, J. M.
    Menter, A.
    Lacour, J. P.
    Chimenti, S.
    Hu, C. C.
    Day, R. M.
    Shah, K.
    Griffiths, C.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2016, 57 : 67 - 67
  • [24] Apremilast in moderate to severe plaque psoriasis: 32-week results in patients with nail, scalp, and palmoplantar involvement (ESTEEM 2)
    Sebastian, M.
    Crowley, J.
    Cather, J.
    Gooderham, M.
    Girolomoni, G.
    Ferrandiz, C.
    Hu, C. C.
    Day, R.
    Beylot-Barry, M.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2015, 13 : 94 - 95
  • [25] Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial
    Fiorillo, Loretta
    Becker, Emily
    de Lucas, Raul
    Belloni-Fortina, Anna
    Armesto, Susana
    Elewski, Boni
    Maes, Peter
    Oberoi, Rajneet K.
    Paris, Maria
    Zhang, Wendy
    Zhang, Zuoshun
    Arkin, Lisa
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (06) : 1232 - 1239
  • [26] Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial
    Ohtsuki, Mamitaro
    Okubo, Yukari
    Komine, Mayumi
    Imafuku, Shinichi
    Day, Robert M.
    Chen, Peng
    Petric, Rosemary
    Maroli, Allan
    Nemoto, Osamu
    JOURNAL OF DERMATOLOGY, 2017, 44 (08): : 873 - 884
  • [27] Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
    Menter, Alan
    Tyring, Stephen K.
    Gordon, Kenneth
    Kimball, Alexa B.
    Leonardi, Craig L.
    Langley, Richard G.
    Strober, Bruce E.
    Kaul, Martin
    Gu, Yihua
    Okun, Martin
    Papp, Kim
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 58 (01) : 106 - 115
  • [28] Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial
    Gold, Linda Stein
    Papp, Kim
    Pariser, David
    Green, Lawrence
    Bhatia, Neal
    Sofen, Howard
    Albrecht, Lorne
    Gooderham, Melinda
    Chen, Mindy
    Paris, Maria
    Wang, Yao
    Duffin, Kristina Callis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 86 (01) : 77 - 85
  • [29] A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial
    Cutolo, Maurizio
    Myerson, Gary E.
    Fleischmann, Roy M.
    Liote, Frederic
    Diaz-Gonzalez, Federico
    Van den Bosch, Filip
    Marzo-Ortega, Helena
    Feist, Eugen
    Shah, Kamal
    Hu, ChiaChi
    Stevens, Randall M.
    Poder, Airi
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (09) : 1724 - 1734
  • [30] Efficacy of Apremilast in Patients With Moderate-to-Severe Genital Psoriasis: Body Surface Area Subgroup Results From the Phase 3 DISCREET Trial
    Merola, Joseph F.
    Parish, Lawrence Charles
    Guenther, Lyn
    Lynde, Charles
    Lacour, Jean-Philippe
    Staubach, Petra
    Cheng, Sue
    Deignan, Cynthia
    Chen, Mindy
    Papp, Kim
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB158 - AB158
12345